liqrev Drug Patent Profile

When do Liqrev patents expire, and what generic alternatives are available?

Liqrev is a drug marketed by Cmp Dev Llc and is included in one NDA. There are four patents protecting this drug.

This drug has nine patent family members in nine countries.

The generic ingredient in LIQREV is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Liqrev

A generic version of liqrev was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Summary for liqrev

International Patents:	9
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for liqrev
What excipients (inactive ingredients) are in liqrev?	liqrev excipients list
DailyMed Link:	liqrev at DailyMed

See drug prices for liqrev

Pharmacology for liqrev

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

US Patents and Regulatory Information for liqrev

liqrev is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No			Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No			Y
Cmp Dev Llc	LIQREV	sildenafil citrate	SUSPENSION;ORAL	214952-001	Apr 28, 2023		DISCN	Yes	No			Y

International Patents for liqrev

See the table below for patents covering liqrev around the world.

Country	Patent Number	Title	Estimated Expiration
China	111683683	PDE V抑制剂的液体口服制剂 (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
European Patent Office	3731870	FORMULATIONS ORALES LIQUIDES POUR INHIBITEURS DE PDE V (LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS)
Australia	2018397436	Liquid oral formulations for PDE V inhibitors

Supplementary Protection Certificates for liqrev

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	5/1999	Austria		PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756	SPC/GB99/004	United Kingdom		PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622

Liqrev Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Liqrev (Sildenafil)

Introduction to Liqrev

Liqrev is a formulation of sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed for the treatment of pulmonary arterial hypertension (PAH) and, in some cases, erectile dysfunction (ED). It is available as an oral powder for reconstitution, making it particularly useful for patients with dysphagia.

Market Size and Growth Projections

The sildenafil drug market, which includes Liqrev, is anticipated to experience significant growth in the coming years. The market size is projected to reach $4.56 billion by 2030, up from $2.90 billion in 2023, with a compound annual growth rate (CAGR) of 6.7% during the forecast period[1][4].

Key Drivers of the Market

Several factors are driving the growth of the sildenafil market, including:

• Rising Prevalence of Erectile Dysfunction (ED): The increasing incidence of ED, particularly among the aging population, is a major driver.
• Growing Geriatric Population: As the global population ages, the demand for ED treatments is expected to rise.
• Increasing Awareness: Greater awareness about ED treatment options and the reduction of stigma around the condition are encouraging more men to seek medical help.
• High Risk Factors: Conditions such as obesity, diabetes, and smoking contribute to the higher incidence of ED, thereby increasing the demand for sildenafil[1][4].

Geographical Market Dynamics

• North America: Currently the dominant region in the sildenafil market, North America benefits from high medical awareness, advanced healthcare infrastructure, and the presence of major pharmaceutical companies. The introduction of generic versions has also reduced price points, making the drug more accessible[1][4].
• Asia Pacific: This region is expected to emerge as a lucrative market due to improving healthcare access in countries like China and India, coupled with rising standards of living[1].

Product Formulations and Innovations

Liqrev, as a ready-made liquid formulation of sildenafil, offers a significant advantage for patients with dysphagia. Launched by CMP Pharma, Inc. in June 2023, Liqrev is the first FDA-approved liquid formulation of sildenafil, designed to improve exercise ability and delay clinical worsening in patients with PAH[4].

Pricing and Accessibility

The cost of Liqrev can be substantial, with a supply of 122 milliliters costing around $2,005 for cash-paying customers. However, generic versions of sildenafil are available at significantly lower prices, such as $111.50 for 112 milliliters, making the treatment more accessible to a broader population[2].

Market Opportunities

• Generic Accessibility: Favorable regulations supporting generic accessibility can drive volume growth and reduce costs for patients.
• Educational Campaigns: Emphasis on ED management during primary check-ups and educational campaigns aimed at destigmatizing ED can increase patient awareness and adherence to treatment.
• Innovative Delivery Methods: Advancements in drug formulations, such as oral jellies, oral sprays, and tropical gels, enhance patient compliance and accessibility[1][4].

Challenges and Restraints

• Price Wars: Maintaining brand loyalty with flagship products amid intense price competition from generics poses a significant challenge.
• Regulatory and Market Dynamics: The complex interplay between originator and generic medicines, especially in low and middle-income countries, can affect market share and pricing strategies[1][3].

Competitive Landscape

The sildenafil market is highly competitive, with key players including Pfizer, Teva Pharmaceuticals, Aurobindo Pharma, and others. These companies are engaged in various strategies such as marketing campaigns, educational programs, and collaborations with healthcare providers to enhance patient education and outreach efforts[1][4].

Recent Developments and Innovations

• Digital Marketing: The use of digital platforms and social media has significantly improved awareness and acceptance of ED treatments, driving demand for sildenafil.
• Collaborations: Partnerships between pharmaceutical companies and healthcare providers are enhancing patient education and promoting the use of sildenafil for various therapeutic applications beyond ED[4].

Financial Implications

The financial trajectory of Liqrev and the broader sildenafil market is influenced by several factors:

• Revenue Growth: The market is expected to grow substantially, driven by increasing demand and innovative product offerings.
• Cost Management: The availability of generic alternatives and the introduction of new formulations like Liqrev are critical in managing costs and ensuring affordability for patients.
• Regulatory Support: Favorable regulatory environments that support generic accessibility and reduce price points are crucial for market growth[1][4].

Key Takeaways

• The sildenafil market, including Liqrev, is projected to grow significantly, driven by rising ED prevalence and increasing awareness.
• North America and Asia Pacific are key regions driving market growth.
• Innovative formulations and generic accessibility are crucial for market expansion.
• Educational campaigns and digital marketing are vital in destigmatizing ED and promoting treatment adherence.
• The competitive landscape is marked by intense price competition and strategic collaborations among pharmaceutical companies.

FAQs

1. What is Liqrev used for? Liqrev is used for the treatment of pulmonary arterial hypertension (PAH) and, in some cases, erectile dysfunction (ED), particularly for patients with dysphagia.

2. How much does Liqrev cost? The cost of Liqrev can be around $2,005 for a supply of 122 milliliters, although generic versions of sildenafil are available at lower prices.

3. What are the key drivers of the sildenafil market? The key drivers include the rising prevalence of ED, growing geriatric population, increasing awareness about ED treatment options, and high risk factors like obesity, diabetes, and smoking.

4. Which regions are expected to dominate the sildenafil market? North America currently dominates the market, but Asia Pacific is expected to emerge as a lucrative region in the coming years.

5. What are the challenges faced by the sildenafil market? Challenges include maintaining brand loyalty amid intense price competition from generics and navigating complex regulatory and market dynamics.

Cited Sources:

1. Coherent Market Insights - Sildenafil Drug Market Size & Share Analysis - Growth Trends
2. Drugs.com - Liqrev Prices, Coupons, Copay Cards & Patient Assistance
3. PubMed - The market dynamics of generic medicines in the private sector of 19 low and middle income countries
4. IndustryARC - Sildenafil Citrate Market - Forecast(2024 - 2030)